Sign up online today & collaborate
or click here to find out more
Edinburgh, UK – Synpromics Ltd, the leading synthetic promoter company, is pleased to announce an extension to the original collaboration with uniQure announced in January 2015, which focused on the development of synthetic promoters with up-regulated liver cell specific activity suitable for gene expression using an AAV vector.
Synpromics has successfully met the project goals and produced synthetic promoters, of fewer than 250 base pairs, that show high levels of activity. Synpromics and uniQure have now agreed to extend the programme under which Synpromics will further apply its technology and know-how to create ultra-small synthetic promoters. Additionally, Synpromics has developed a proprietary vector screening technology which allows the in vivo screening of synthetic promoter candidates for specificity and activity.
Dr David Venables, CEO of Synpromics, commented, “We are delighted that the first collaboration with uniQure has produced such exciting results and has met its goals. With the agreed extension announced today we can further apply our technology to make shorter promoters and so increase the efficacy of gene therapy. Gene therapy is an exciting new therapeutic area and we are pleased to be able to make a significant contribution”